Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Liabilities and Shareholders Equity (2016 - 2025)

Vistagen Therapeutics' Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $65.1 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 29.52% year-over-year to $65.1 million; the TTM value through Dec 2025 reached $299.2 million, down 30.73%, while the annual FY2025 figure was $84.3 million, 31.79% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $65.1 million at Vistagen Therapeutics, down from $80.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $131.1 million in Q4 2023 and bottomed at $15.0 million in Q2 2023.
  • The 4-year median for Liabilities and Shareholders Equity is $92.3 million (2024), against an average of $88.2 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 1775.88% in 2021 before it crashed 39.3% in 2025.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $90.5 million in 2021, then soared by 44.77% to $131.1 million in 2023, then dropped by 29.57% to $92.3 million in 2024, then fell by 29.52% to $65.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Liabilities and Shareholders Equity are $65.1 million (Q4 2025), $80.9 million (Q3 2025), and $68.9 million (Q2 2025).